The European Commission has published the Horizon 2020 Monitoring report for 2015. This document includes, among others, the 50 institutions that have received the most funding for research in the calls made up to 2015.
Blanca Molins rep el premi Julián García Sánchez de recerca en temes de la visió Read the rest of this entry »
Scientists from Salk Institute for Biological Studies showed that One clue to halting or reversing aging lies in the study of cellular reprogramming, a process in which the expression of four genes known as the Yamanaka factors allows scientists to convert any cell into induced pluripotent stem cells (iPSCs) Like embryonic stem calls, iPSCs are capable of dividing indefinitely and becoming any cell type present in our body. Dr. Juan Carlos Izpisúa Belmonte, professor in Salk’s Gene Expression Laboratory, is the senior author of the paper, published in Cell, in which also participated Dr. Josep Maria Campistol, CEO and nephrologist in Hospital Clínic, and researcher in IDIBAPS. Scientists from Universidad Católica de Murcia, among others, have also been involved. Read the rest of this entry »
On Monday, December 12, Palau Macaya hosted the presentation of the selected projects in the second edition of CaixaImpulse, two of which are from IDIBAPS.
Researchers from Hospital Clínic and IDIBAPS lead an international study in which they have developed a genomic test to predict the response to chemotherapy in breast cancer. Hospital Clínic of Barcelona will be the first hospital in the world to implement this third generation test. This test is based on the data produced by the second-generation test PAM50, and for which Hospital Clínic is one of the reference centers. The article, published today in the journal Clinical Cancer Research, has been coordinated by Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic, the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS and the Translational Genomics group of the Vall d’Hebron Institute of Oncology (VHIO). The study has involved several hospitals in Spain within the GEICAM breast cancer co-operative group, researchers from the University of North Carolina (USA), the Royal Marsden Foundation Trust in London, the University of Otago (New Zealand) and The University of Edinburgh (Scotland).